Tetra Bio-Pharma Inc. Announces Listing of Warrants

ORLEANS, ON, May 30, 2018 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that a total of 11,500,000 common share purchase warrants (the "Warrants") of the Corporation will be listed and posted for trading under the symbol TBP.WT on the TSX Venture Exchange effective on or about June 1, 2018.

The Warrants were issued in connection with the Company's bought deal prospectus offering of Units (the "Units") that closed on March 5, 2018. Each Unit consisted of one common share (a "Common Share") and one Warrant. Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price equal to $1.30 at any time before March 5, 2021.

The Warrants are governed by the terms of a Warrant Indenture dated March 5, 2018 between the Company and Computershare Trust Company of Canada as warrant agent, a copy of which is available under the Company's profile at www.sedar.com. For further details regarding the Warrants, please refer to the Warrant Indenture.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation's business plan; the success of the Rx Princeps^TM product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps^TM product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation's public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

SOURCE Tetra Bio-Pharma Inc.

For further information, please contact Tetra Bio-Pharma Inc., Robert (Bob) Béchard, Vice President, Finance & Business Development, [phone]; For investors information, please contact: [email protected]